Safety Reading Notes

Read safety context beside the research guide.

The NADA source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 15245490

PubMed For Dummies Article

NADA Evidence Review: the long-form source walk-through

Quick read
  • NADA currently has 13 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 15245490
  • The evidence classes most visible in the row language are mechanistic or pharmacological (12), and insufficient (1). PMID 29082315
  • The study-design language most visible in the row language is Animal study (7), Cellular or in vitro study (5), and Narrative or expert review (1). PMID 17459108
  • The repeated topics are NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o... (13), which tells the reader where to start opening PubMed and DOI links. PMID 24644287

Start with the research question

NADA is built from 13 source-backed evidence row(s) and 13 research source(s). The current evidence classes read as mechanistic or pharmacological (12), and insufficient (1), and the study-design language most often reads as Animal study (7), Cellular or in vitro study (5), and Narrative or expert review (1). PMID 15245490

The row-level question is not simply whether NADA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o... (13). PMID 29082315

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 27189587

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 20354008

Mechanistic evidence 12 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 15289293

Limits and uncertainty 1 row

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 15006899

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 25995819

Where this page has the most source density

The largest bucket surfaced for this page is NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 15245490

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 29082315

Bucket chapters: what the literature is circling

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: mechanistic or pharmacological

12 research sources 12 rows (1132-1143) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: mechanistic or pharmacological. It currently draws from 12 research source(s), so the exact study type matters. PMID 15245490

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 15245490

  • Evidence row 1132

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients men... PMID 15245490

  • Evidence row 1143

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study desi... PMID 17984664

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: insufficient

1 research source 1131 Evidence class: insufficient

This bucket summarizes source-backed rows focused on NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...: insufficient. It currently draws from 1 research source(s), so the exact study type matters. PMID 29082315

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 29082315

  • Evidence row 1131

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design:... PMID 29082315

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (12 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 15245490

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 29082315

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 28701511
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 16760924
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 33568652

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 15245490

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 29082315

Source-reading checklist for NADA

  1. Open the linked PubMed or DOI record. PMID 17984664
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 15245490
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 29082315
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 17459108
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 24644287

Source Notes

NADA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1131

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 29082315

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.
  2. Evidence row 1132

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15245490

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.
  3. Evidence row 1133

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17459108

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.
  4. Evidence row 1134

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24644287

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
  5. Evidence row 1135

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27189587

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Endovanilloids are potential activators of the trigeminovascular nocisensor complex.
  6. Evidence row 1136

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20354008

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population.
  7. Evidence row 1137

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15289293

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.
  8. Evidence row 1138

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15006899

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.
  9. Evidence row 1139

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25995819

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.
  10. Evidence row 1140

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 28701511

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.
  11. Evidence row 1141

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16760924

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
  12. Evidence row 1142

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33568652

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
  13. Evidence row 1143

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17984664

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.